(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 February 2014 (27.02.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/031610 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *C12Q 1/68* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2013/055747

(22) International Filing Date:
20 August 2013 (20.08.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/691,625	21 August 2012 (21.08.2012)	US
61/758,097	29 January 2013 (29.01.2013)	US
61/761,279	6 February 2013 (06.02.2013)	US
61/783,796	14 March 2013 (14.03.2013)	US
61/805,797	27 March 2013 (27.03.2013)	US
1356994	16 July 2013 (16.07.2013)	FR

(71) Applicants: **SANOFI** [FR/FR]; 54 rue La Boétie, F-75013 Paris (FR). **REGENERON PHARMACEUTICALS INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (US).

(72) Inventors: **ARDELEANU, Marius**; c/o Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Rd, Tarrytown, New York 10591-6707 (US). **GANDHI, Namita**; c/o REGENERON PHARMACEUTICALS INC., 777 Old Saw Mill River Rd, Tarrytown, New York 10591-6707 (US). **GRAHAM, Neil**; c/o Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Rd, Tarrytown, New York 10591-6707 (US). **KIRKESSELI, Stephane, C.**; c/o Sanofi, 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). **KUNDU, Sudeep**; c/o Sanofi, 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). **RADIN, Allen**; c/o Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Rd, Tarrytown, New York 10591-6707 (US). **ROCKLIN, Ross, E.**; c/o Sanofi, 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). **WEINSTEIN, Steven**; c/o Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Rd, Tarrytown, New York 10591-6707 (US). **DAVIDSON HAMILTON, Jennifer**; c/o Regeneron Pharmaceuticals

[Continued on next page]

(54) Title: METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST



Figure 1

(57) Abstract: The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.

WO 2014/031610 A1

Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (US). **MING, Jeffrey**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US).

(74) **Agents**: **VELEMSI, James H.** et al.; Lathrop & Gage LLP, 28 State Street, Suite 0700, Boston, MA 02109 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*